hcm-magazin.de – Date: 20.08.2024
Author: hcm-magazin.de – Source
Novogenia is shifting its focus back to genetic analysis and personalized medicine after a significant role in PCR testing during the pandemic. The company is investing heavily in expanding its capabilities and offerings. In an interview with Dr. Daniel Wallerstorfer, Novogenia’s founder and CEO, he discusses the potential of genetic tests in preventive medicine, the impact of the German § 64e SGB V legislation on genomics, and the growing importance of pharmacogenetics.
Wallerstorfer highlights the benefits of preventive genetic testing, which aims to identify disease risks before symptoms appear, as opposed to traditional “damage control” approaches. He sees significant potential in pharmacogenetics for avoiding adverse drug reactions through tailored treatments. The new § 64e SGB V regulation, providing substantial funding for oncology genomics, is expected to enhance cancer treatment and research.
Despite challenges, Novogenia is committed to advancing its technologies and expanding its facilities, including a major new building project. The company is open to partnerships with various healthcare providers and institutions, aiming to integrate its genetic testing and personalized solutions into broader healthcare practices, although the focus remains on self-pay services due to current limitations in public healthcare funding for prevention.
